CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 20 enrolled
Drug / intervention
17beta Estradiol +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01023178
NCT01023178N/ACompleted

Comparison of Transdermal and Oral Estrogens in Adolescents With Ovarian Failure

Stanford University·interventional·Posted Dec 2, 2009·Updated Jan 20, 2017

In Brief

A clinical study evaluating 17beta Estradiol, Conjugated estrogens, and 2 other interventions for Ovarian Failure, Premature. Completed, enrolled 20 participants across 1 site.

Detailed Summary

To directly compare the safety (by laboratory evaluation) and efficacy (feminization and growth) of three commonly used estrogen preparations in adolescent patients with ovarian failure, either due to congenital causes (Turner syndrome) or medical therapies. We hypothesize that transdermal estrogen will have equivalent efficacy and a more favorable safety profile in comparison with conventional oral estrogen replacement.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 2, 2009
Enrollment StartFeb 1, 2007
Primary CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 16.6 years ago

Interventions

17beta Estradioldrug

Oral pill given daily at increasing doses every 6 months for 18 months.

Conjugated estrogensdrug

Oral pill, started at a low dose taken daily, dose increased every 6 months for 18 months

17Beta Estradiol - transdermaldrug

Transdermal estrogen patch, started at low dose with increasing doses eery 6 months for 18 months

Progesterone, micronizeddrug

Given starting at 18 months